News
-
-
-
PRESS RELEASE
Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial
Inventiva and Hepalys Pharma, Inc. initiate clinical development program of lanifibranor in Japan with dosing of first participant in Phase 1 trial, marking significant progress in partnership -
PRESS RELEASE
Inventiva et Hepalys Pharma, Inc. annoncent le lancement du programme de développement clinique de lanifibranor au Japon avec l'inclusion du premier participant dans l'étude de Phase 1
Inventiva et Hepalys Pharma annoncent le lancement du programme de développement clinique de lanifibranor au Japon avec l'inclusion du premier participant dans l'étude de Phase 1 -
-
-
PRESS RELEASE
Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update
Inventiva reports preliminary 2024 fiscal year financial results and business update, with €9.2 million revenues and €96.6 million cash as of December 31, 2024. Focused on lanifibranor development -
-
-
